Champions Oncology Reports on Shareholder Vote

TL;DR

Champions Oncology held a shareholder vote on Oct 14th. Details to follow.

AI Summary

Champions Oncology, Inc. filed an 8-K on October 15, 2024, reporting on a matter submitted to a vote of its security holders on October 14, 2024. The company, incorporated in Delaware, is involved in Biological Products, excluding diagnostics, and is headquartered in Baltimore, MD.

Why It Matters

This filing indicates a formal process where shareholders are being asked to vote on specific company matters, which could impact corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes or operational risks.

Key Numbers

• 001-11504 — SEC File Number (Identifies the company's filing history with the SEC.)
• 52-1401755 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• CHAMPIONS ONCOLOGY, INC. (company) — Registrant
• October 14, 2024 (date) — Date of earliest event reported
• October 15, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of Incorporation
• BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) (industry) — Standard Industrial Classification
• Baltimore, MD (location) — Business Address

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share CSBR The Nasdaq Stock Market

Filing Documents

• csbr-20241014.htm (8-K) — 46KB
• 0001628280-24-042780.txt ( ) — 167KB
• csbr-20241014.xsd (EX-101.SCH) — 2KB
• csbr-20241014_lab.xml (EX-101.LAB) — 21KB
• csbr-20241014_pre.xml (EX-101.PRE) — 12KB
• csbr-20241014_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On October 14, 2024, Champions Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows: 1. Election of Directors. The seven director nominees named in the Company's 2024 proxy statement were elected to serve for a one-year term expiring at the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes: Director Nominee Votes For Votes Withheld Broker Non-Vote Ronnie Morris, M.D. 8,483,091 685,123 697,813 Joel Ackerman 7,973,309 1,194,905 697,813 David Sidransky, M.D. 7,997,992 1,170,222 697,813 Daniel Mendelson 7,769,799 1,398,415 697,813 Scott R. Tobin 9,167,706 508 697,813 Philip Breitfeld, MD. 9,167,215 999 697,813 Robert Brainin 7,888,299 1,279,915 697,813 2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025, was ratified as follows: Votes For Votes Against Abstain 9,865,571 256 200 3. Non-binding Advisory Resolution Relating to the Compensation of the Company's Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2024 proxy statement, was approved by the following votes: Votes For Votes Against Abstain Broker Non-Vote 9,162,287 2,027 3,900 697,813

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CHAMPIONS ONCOLOGY, INC. (Registrant) Date: October 15, 2024 By: /s/ David Miller David Miller Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR